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Abstract. Mycophenolate mofetil (MMF), an ester prodrug of the 
immunosuppressant mycophenolic acid (MPA), is widely used for 
maintenance immunosuppressive therapy and prevention of renal 
allograft rejection in renal transplant recipients. 
      MPA inhibits inosine monophosphate dehydrogenase (IMPDH), 
an enzyme involved in the “de novo” synthesis of purine 
nucleotides, thus suppressing both T-cell and B-cell proliferation. 
MPA shows a complex pharmacokinetics with considerable inter- 
and intra- patient by between- and within patient variabilities 
associated to MPA exposure. Several factors may contribute to it. 
The pharmacokinetic modeling according to the population 
pharmacokinetic   approach   with          the   non-linear   mixed   effects  
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models has     shown to be a powerful tool to describe the relationships between MMF 
doses and the MPA exposures and also to identify potential predictive patients’ 
demographic and clinical characteristics for dose tailoring during the post-transplant 
immunosuppresive treatment.  
 
Introduction 
 
 Mycophenolic acid based therapies are widely used in combination 
with calcineurin inhibitors (cyclosporine, tacrolimus, sirolimus) as 
maintenance immunosuppression in renal transplantation. Mycophenolate 
mofetil (MMF, brand name cellCept®, Hoffmann-La Roche, Basel, 
Switzerland) is one of the therapies currently used. In this context, there 
has been considerable interest in immunosuppressive regimens which 
permit reduction or elimination of calcineurin inhibitor (CNI)-associated 
and other chronic toxicities while maintaining adequate immune-
suppresion [1]. MPA exposure values show a high variability partly 
attributable to its complex pharmacokinetics [2,3]. Several factors as 
albumin concentrations, renal function, co-medication and genetic 
polymorphism, may contribute to it [2-6]. Recent literature supports the 
notion that therapeutic drug monitoring (TDM) of MPA improves 
monitoring of kidney transplant patients on high risk of acute rejection or 
on calcineurin inhibitor minimization protocols [7,8]. The current review 
discusses the pharmacokinetics of MPA and its conjugated metabolites as 
well as the population pharmacokinetic models developed to describe it. 
Results of an integrated model recently developed by our group including 
the MPA protein binding, the pharmacokinetics (PK) of both metabolites 
(7-O-MPA glucuronide (MPAG) and acyl-glucuronide (AcMPAG) and 
the influence of co-medication and of multidrug resistance associated 
protein 2 (MRP2) polymorphism on the PK of MPA and its metabolites 
are also presented. 
 
1. Chemistry of mycophenolic acid and its metabolites 
 
 Mycophenolic acid (MPA) is an antibiotic substance derived from 
Penicillium stoloniferum. Mycophenolate mofetil (MMF) is the 2,4-
morpholinoethyl esther of MPA [9]. It was developed as a prodrug 
because the low oral bioavailability of MPA. Molecular structures of  
mycophenolic acid and its conjugated metabolites, i.e. the phenolic MPA 
7-O-glucuronide (MPAG) and the acyl-glucuronide (AcMPAG) are 
summarized in Fig. 1. 
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Figure 1. Molecular structures of mycophenolate mofetil (MMF), mycophenolic acid 
(MPA) and its metabolites, i.e. phenolic MPA 7-O-glucuronide (MPAG) and  acyl-
glucuronide (AcMPAG). 
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Figure 2. Purine biosynthetic pathways and mycophenolic acid activity. 
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2. Pharmacodynamics of mycophenolic acid 
 
 MPA blocks the “de novo” biosynthesis of purine nucleotides by 
inhibition of the enzyme inosine monophosphate dehydrogenase [10-12]. 
Mycophenolic acid is important because of its selective effects on the 
immune system. As displayed in Fig. 2, it prevents the proliferation of T-
cells, lymphocytes, and the formation of antibodies from B-cells. It also may 
inhibit recruitment of leukocytes to inflammatory sites.  
 
3. Pharmacokinetics of mycophenolic acid 
 
 The pharmacokinetic processes that take place when MMF is given 
orally are summarized in Fig. 3. After its oral administration, MMF is rapidly 
and essentially, completely absorbed, and then completely hydrolised to 
MPA, by estearases in the gut wall, blood, liver and tissue [2]. Oral 
bioavailability of MPA, after MMF administration ranges from 80.7% to 
94% [3]. MPA is mainly metabolized by glucuronidation by several uridine 
diphosphate glucuronosyltransferases (UGTs) in the liver, gastrointestinal 
tract and kidneys into its inactive MPA 7-O-glucuronide (MPAG) and the 
pharmacologically active acyl-glucuronide (AcMPAG) [13]. Renal clearance 
of unchanged MPA is negligible [3] while MPAG and AcMPAG are mainly 
excreted into urine via active tubular secretion mediated by MRP2 (multidrug 
resistance-associated protein 2). In the liver MPA is taken up into 
hepatocytes, glucuronidated to MPAG which is then excreted into bile 
through MRP2  and then de-conjugated back to MPA by gut bacteria [14]. 
The formed MPA is then reabsorbed in the colon. Biliary secretion of 
MPAG, leading to this enterohepatic recirculation (EHC), contributes 
approximately 40% to the area under the plasma concentration-time curve 
(AUC) and  is considered as the major cause of the secondary peak (observed 
from 6 to 12 h after oral administration) of MPA in plasma [15]. The EHC is 
also assumed to occur for the conjugated metabolite AcMPAG [16]. 
Ciclosporin causes a decrease in the biliary secretion of MPAG and thereby 
decreases MPA plasma levels and its exposure [14,17,18]. This interaction 
has been associated with MRP2 inhibition of biliary secretion of MPAG and 
MPA by ciclosporin [19,20]. On the other hand, MPA is extensively bound to 
serum albumin [21] and a protein binding ranging from 97% to 99%  has 
been reported in patients with normal renal and liver functions [2]. Although 
lower, MPAG also displays a high albumin protein binding (82%) in stable 
patients [3]. Therefore, competition between MPA and MPAG by albumin 
binding may exist. The interplay between all the processes above described 
leads to large between-patient and within–patient variabilities associated to 
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the exposure of MPA and its metabolites in renal transplant patients, as it has 
been previously reported [2,3]. 
 
4. Pharmacokinetic variability 
 
 Renal function, serum albumin concentrations, haemoglobin levels, 
delayed graft function and immunosuppressive co-medication have been 
described as factors contributing to the variability and time-dependent 
pharmacokinetics described for MPA [6,22-27]. Previous studies [28] 
demonstrated that decreased albumin plasma concentrations lead to increased 
free fractions both of MPA and MPAG. As consequence, relatively more free 
MPA (fMPA) is available for elimination resulting in decreased total MPA 
(tMPA) exposure. However, the fMPA exposure is unaffected. This often 
happens with drugs of low extraction rate [29] as it is the case of MPA [30] 
and it implies that, in these cases, tMPA exposure could drop below the 
therapeutic values, so that MMF dose should be increased in order to avoid 
acute   rejection.  The influence of  renal  function on the  pharmacokinetics  of  
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Figure 3. Pharmacokinetics of mycophenolic acid (MPA) and its metabolites, 
phenolic MPA 7-O-glucuronide (MPAG) and acyl-glucuronide (AcMPAG) after 
mycophenolate mofetil (MMF) oral administration. 
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MPA and its conjugates has also been widely reported [22,28]. As it should 
be expected, a very poor renal allograft function (i.e. CLCR values around    
10 mL/min), mainly occurring in the earliest phases after transplantation, 
have major effects on both MPAG and AcMPAG exposures than on 
exposures to tMPA or fMPA. According to De Winter et al. [28], depending 
on the calcineurin inhibitor (CNI) given to patients with impaired renal 
function, differential effects on tMPA and fMPA exposures can be observed. 
In the case of ciclosporin tMPA exposure decreases and fMPA exposure 
remains the same. In patients under tacrolimus an increased exposure to 
tMPA and a small increase in fMPA exposure are observed. 
 The justification of this is that under tacrolimus, accumulation of MPAG, 
as consequence of low renal function, results in increased transport of MPAG 
to the gallbladder leading to increased recirculation of MPAG to MPA. 
Because the extra-recirculation, MPAG does not accumulate to an extent 
where it can displace MPA from its protein binding sites. It results in 
increased tMPA and fMPA due to extra-recirculation and no change in 
unbound fraction of MPA. By contrast, in patients under ciclosporin the 
accumulated MPAG following renal impairment cannot be compensated by 
increased recirculation because MRP2 transport is inhibited by ciclosporin. 
As a result MPAG displaces MPA from its protein binding sites, leading to 
an increased fraction of fMPA. The increased fMPA exposure is immediately 
compensated for by an increase in MPA glucuronidation according to the 
theory of restrictively cleared drugs. Therefore, in this case the result is 
decreased tMPA exposure, unchanged fMPA exposure and an increased 
fMPA fraction. The genetic factors controlling the level of UGT-mediated 
MPA metabolism [31-34] and the MRP2-mediated conjugated metabolites 
transport [35] can also partly explain the observed variability in MPA 
exposure. The large variability and the MPA narrow therapeutic index lead to 
optimization of the immunosuppressive regimen in order to avoid the risk of 
acute rejection (AR), and to prevent adverse-effects associated with long-
term immunosuppressive treatment.  
 
5. Relationship between MPA exposure and clinical outcome 
 
 In vitro studies have suggested that the fMPA concentrations may more 
accurately reflect the degree of immunosuppressive action of the drug than 
does the concentrations of tMPA [21]. The fMPA concentrations have been 
shown to correlate with the risk of leukopenia and infection [24]. However, 
although a relationship between fMPA exposure and the risk for acute 
rejection should be expected, it has not been demonstrated yet. More 
information is needed about the relationship between fMPA exposure and the 
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risk for acute rejection and side effects to interpret the clinical effect of 
changes in protein binding of MPA. Alterations in both albumin 
concentrations and renal function have little effect on fMPA exposure and 
thereby little clinical relevance. However special attention must be paid on 
patients under tacrolimus with very poor renal function, as the increased 
fMPAG can cause elevated exposure to both tMPA and fMPA. Regarding to 
tMPA, a correlation between tMPA exposure and the risk of acute rejection 
has been reported [36]. The proper tMPA exposure (AUC) range to avoid 
acute rejection has been recommended to be 30-60 μg·h/mL when combined with 
ciclosporin [36-39]. Under this co-medication there is no further reduction in 
acute rejection at AUC values >60 (mg/L)·h [36]. Therefore, avoidance of higher 
exposure would seem prudent on the basis of these results. For patients under 
tacrolimus, the range of 30-60 μg·h/mL has also been suggested for MPA 
exposure [39]. Regarding to patients with low albumin concentrations or poor 
renal function, accompanied by low tMPA exposures, candidates to increased 
doses of MMF to avoid acute rejection, the dose increase will also increase the 
fMPA exposure. Therefore, the neutrofil count in these patients should be 
accurately monitored, as there may be a potential increased risk of leucopenia and 
infections. In that sense it should be noted that fMPA exposures > 0.14 (mg/L)·h, 
are expected to increase the risk of adverse events. This cut-off has been 
established in a pediatric study in the early post-transplant phase [24]. On the 
other hand, measurement of the pharmacologically active metabolite AcMPAG 
could also provide information about proper exposures to it in order to avoid the 
risk for adverse events. The population approach has shown to be a powerful tool 
for these purposes. The characteristics of this approach are reviewed below. 
  
6. Population pharmacokinetic approach: Non linear mixed 
effects modeling 
 
 According to the FDA Guidance [40], population pharmacokinetics, is 
the study of the sources and correlates of variability in drug concentrations 
among individuals who are the target patient population receiving clinically 
relevant doses of a drug of interest. It allows to identify the determinants of 
pharmacokinetic variability, explaining between-patient differences in drug 
exposure and can provide clinically applicable models for dose tailoring. 
With this approach, the description of the pharmacokinetics of a given drug 
in the target population can be performed by determining a) what is the mean 
population pharmacokinetic behaviour, b) which factors influence the mean 
population PK behaviour and, c) what is the uncertainty degree associated to 
the mean population PK behaviour, i.e. the magnitude of between-patient 
variability and residual error can be quantified. Its advantages when compared 
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to the classical approach are numerous such as being able to analyze 
concentration-time data of parent compound and metabolites, data from several 
doses or plasmatic and urine data, simultaneously. Moreover, apart from 
analyzing dense data (intensive sampling in each individual) it allows to 
analyze unbalanced data and sparse data (few samples per individual) coming 
from observational studies, phase II/III/IV clinical studies or from special 
populations (neonates, children, elderly, transplantation, HIV) or from 
therapeutic drug monitoring (TDM).  
 Non linear mixed effects models implemented in several softwares are the 
most widely used for these purposes [41]. Once validated, the models developed 
with this approach will allow, a) description and a better knowledge of the  
pharmacokinetic profile of a given drug in the target population, b) simulations of 
new scenarios to predict exposures to different dosing regimens, to evaluate 
consequences of alternative sampling designs, or to evaluate the impact of 
changes in patients’ characteristics, and c) calculation of the first dose and dose 
tailoring during the therapeutic drug monitoring, in order to achieve the target 
value of a given PK parameter (in general, AUC or area under the curve, peak or 
through concentrations) demonstrated to be the best marker of efficacy. 
Regarding to the last point, it should be noted that computer programs designed 
for dose optimisation for individual patients to be used as a part of routine clinical 
care, exist [42]. These programs require the implementation of the PK parameters 
estimated through the non linear mixed effects modeling.  
 In the mixed-effects modeling context [41], the collection of population 
characteristics is composed of population mean values (derived from fixed-
effects parameters) and their variability within the population (generally the 
variance-covariance values derived from random-effects parameters). This 
approach allows to estimate directly the parameters of the population from 
the full set of individual concentration values. The individuality of each 
subject is maintained and accounted for, even when data are sparse. Fig. 4 
summarizes the relationship between fixed and random effects in a 
population PK model. According to this and taking into account one of the 
PK parameters, i.e. clearance (CL), it is assumed that the deviations of 
individual plasmatic clearances of subject 1 (CL1) or 2 (CL2) from the mean 
population value ( CL ) are given by η1CL and η2CL, respectively (left panel). 
The set of values of etas (ηi) of all individuals in the target population is 
assumed to follow a normal distribution of mean equal to zero and variance 
ω2.  Moreover, the set of deviations of the observed concentrations in each 
individual at a given sampling time j (open circles), from the individual 
predictions by the model (continuous lines or f(CL1), f(CL2), or f(CLi) for the 
i subject), given by εij, in general (i denoting the individual, i.e. i=1,2,..n; and 
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j the sampling time, i.e.,j=1,2,…t) are also assumed to follow a normal 
distribution of mean equal to zero and variance σ2 (right panel). f( CL ) 
represents the concentrations predicted for an individual of the target 
population showing the typical clearance value equal to the mean population 
value, CL . In summary, the population parameters estimated by the non 
linear mixed approach are the following: 
 
a) the fixed effects, i.e. the mean population pharmacokinetic 
parameters as CL or the corresponding regression parameters when 
there is a stististically significant relationship between the PK 
parameters and continuous (age, body weight, creatinine clearance, 
doses or exposure parameters corresponding to  co-medication…) or 
discontinuous (gender…) covariates.  
b) the variances of the η and  ε distributions, that is ω2 and  σ2, 
respectively..  
 
 During the estimation process the η and  ε values for each individual will 
be calculated and thus the individual PK parameter values obtained to be 
used for dose tailoring during the TDM. However, before that, the validation 
or evaluation of the predictability of the model developed is required. Internal 
or external validation techniques can be applied for this purpose [40]. 
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Figure 4. Relationship between fixed effects and random effects in the non linear 
mixed effects approach. 
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7. Population pharmacokinetic modeling of mycophenolic acid 
and its metabolites 
 
 Several MPA population pharmacokinetic models have been previously 
developed trying to identify the sources of variability of MPA 
pharmacokinetics after MMF oral administration [4,6,28,34,43-48]. Some of 
them have allowed to describe the second MPA plasma peak by including the 
EHC in the modeling process [34, 49], as the influence either of changes of 
protein binding [28,47], or of genetic polymorphism in UGT on MPA 
exposure [34]. Recently our group has addressed its work on the 
simultaneous modeling of total and free MPA as total MPAG and AcMPAG 
concentration vs time data proceeding from the PK sub-study of the 
Symphony study [50]. In the Symphony PK sub-study the effect of four 
different immunosuppressive therapies on the PK of MPA was evaluated. 
Briefly, patients randomized in four groups were given fixed doses of MMF 
(1 g twice daily) together with either standard doses of ciclosporin (group A), 
low doses of ciclosporin (group B) or low doses of the immunosuppressive 
macrolides that is to say tacrolimus (group C) or sirolimus (group D). PK 
sampling was performed on 5 occasions (on day 7 and at 1, 3, 6 and 12 
months after transplantation) during the first year after transplantation and 
each time tMPA, fMPA, tMPAG and tAcMPAG exposures were measured. 
Results corresponding to the non-compartmental analysis of this study [50] 
indicated that tMPA and fMPA exposures were lower in patients receiving 
ciclosporin compared to those that were given macrolides. In contrast, 
exposures to the metabolites MPAG and acylMPAG were higher in patients 
treated with ciclosporin compared to the others (Fig. 5). 
 Moreover, in general, a trend to increased tMPA and fMPA exposures 
and decreased tMPAG and tAcMPAG exposures with post-transplant time 
was observed (Fig. 5). This was attributable to the decreasing and increasing 
of MPA and MPAG/AcMPAG clearances, respectively, with post-transplant 
time. On the other hand, Lloberas et al. [35], reported statistically lower 
tMPA and fMPA exposures in patients treated with macrolides being 
homozygous (TT) or heterozygous (CT) carriers of the MRP2 C24T single 
nucleotide polymorphism (SNP) vs non carriers (CC), after having 
investigated the influence of genetic polymorphism of MRP2-mediated 
transport on the MPA exposures in all groups of treatment. It should be noted 
that this effect could not be observed in the group of patients treated with 
ciclosporin. The time-dependent clearance found in this study was in 
agreement with results of  previous studies [4,6,45]. As previously reported, 
ciclosporin dose tapering and  improvement of the renal function along the 
post-transplant  period  can be among others,    some  of the  causes of it.  Since 
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Figure 5. Normalized by dose exposure values given by AUCs (area under the the 
curve) observed for tMPA, fMPA, tMPAG and tAcMPAG, during the first three post-
transplant months of the PK sub-study of the Symphony study [40]. 
 
MPA is a low extraction rate drug, the low albumin concentrations associated 
to a delayed graft function during the early post-transplant stages can also 
lead to higher MPA clearances values at the early stages vs the late. On the 
other hand, inhibition of MRP2 transport by ciclosporin, in patients treated 
with it, leads to decreased MPAG biliar excretion that in turns results in 
decreased EHC, increased MPAG and AcMPAG exposures and decreased 
MPA exposures  when compared to the others. Regarding to the influence of 
C24T SNP, results of this study suggested a lower activity of transport of 
MPAG or AcMPAG through MRP2 in presence of C24T SNP that led to a 
decreased EHC, followed by lower MPA exposure and subsequently lower 
MPAG or AcMPAG exposures caused by its decreased formation, when 
compared to the non carrier (CC) genotype. This was only evidenced under 
macrolides when the effect of ciclosporin was not masking that of the SNP. 
Prompted by these results, a population pharmacokinetic model to allow the 
description of all these processes was developed (Fig. 6) (submitted for 
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publication). The pharmacokinetics of fMPA, tMPA, tMPAG and tAcMPAG 
were best described by an integrated model consisting on three linked 
compartment models; i.e.  two two-compartment models for fMPA and 
tMPAG and a one-compartment model for tAcMPAG (Fig. 6). The model 
was parameterized in terms of volumes of distribution (V) and plasmatic 
(CL) and distributional (CLD)clearances. An albumin compartment was also 
linked directly to the central compartment of fMPA to describe its binding to 
this plasmatic protein (KB=binding rate constant). EHC could not be 
successfully modeled. 
 According to this model, after oral administration, MMF was transformed 
to and absorbed as MPA according to a time lagged first order kinetic process. 
Once in the systemic circulation MPA was simultaneously bound to albumin 
(bMPA) and the free fraction (fMPA) distributed and eliminated.  
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Figure 6. Schematic representation of the final pharmacokinetic model to 
simultaneously describe the protein binding of free mycophenolic acid (fMPA) and its 
conversion to its phenolic 7-O-glucuronide (MPAG) and acyl-glucuronide 
(AcMPAG) conjugates by first order processes, after oral administration of 
mycophenolate mofetil. Dashed lines correspond to the part that could not be 
successfully modeled. bMPA: MPA bound to albumin. 
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 The fMPA protein binding was best described by a linear model 
(bMPA=KB·fMPA) as previously reported by Van Hest et al [46]. This might 
be due to the fact that the fMPA concentrations found in the current study 
(from 0.000019 to 0.005573 mmol/L) were far below the median plasma 
albumin concentrations of the studied population (42 g/L or 0.6087 mmol/L) 
and no saturation of the binding sites could be achieved. Obviously, taking 
into account at least one binding site to albumin, the protein binding would 
be hardly saturated with the current fMPA concentrations. It should be noted 
that fMPA and tMPA concentrations found in our study were around twice 
those observed by Van Hest et al [46] in which higher ciclosporin doses were 
given (around twice those of our study), and nevertheless the linear protein 
binding still described correctly our data. Effectively, unlike our results, Van 
Hest et al. [46], found statistically significant correlations between individual 
KB values and albumin plasma levels and MPAG concentrations. This could 
be attributed to the fact that most of the patients included in the current study 
showed albumin plasma concentrations within the expected range of normal 
healthy adults (43 g/L, ranging from 35 to 53 g/L), even on day 7 of the study 
when delayed graft function should be expected to be more likely.  Only 8 
out of 56 patients and 2 out of 56 patients showed albumin plasma levels less 
than 35 and greater than 53 g/L, respectively; the albumin concentrations of 
the remaining patients were around the study population median level (42 
g/L). Regarding to MPAG concentrations, these were lower in our study than 
those found by Van Hest el al. [46]. The stable renal function of patients and 
also the lower doses of ciclosporin in patients under this co-medication, 
might be the contributing factors to this fact. According to Bullingham et al. 
[3], MPA free fractions (fu) can increase as the MPAG concentrations 
increase to 475 mg/L (957 mmol/L). In our study peak MPAG concentrations 
were lower than 236 mg/L (479 mmol/L) in most patients, so that no 
displacement of bound MPA (bMPA) by MPAG should be expected.  
 Regarding to the elimination process of fMPA it took place by first-order 
kinetic processes as did the metabolites. According to the fm value obtained 
(0.874), MPAG was the major metabolite, while only a 0.126 (1-fm) of fMPA 
present in the blood stream was transformed to AcMPAG. These values were 
in agreement with that reported by Shipkova et al [16], The total clearance 
value of fMPA was the contribution of the clearance of formation MPAG 
(fm·CLMPA) and the clearance of formation AcMPAG ((1-fm)·CLMPA). 
Although EHC modeling could not be included, it does not seem to have a 
relevant impact from a clinical point of view, since the covariates that could 
affect the recycling rate constant (KS) could be incorporated in both the MPA 
and its metabolites clearances. In effect, in agreement with results of the non-
compartmental analysis, an statistically significant relationship was found 
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between CLMPA and ciclosporin through concentrations in patients under 
ciclosporin, in such a way that CLMPA increased with it and was higher in C24 
SNP homozygous (TT) or heterozygous (CT) carriers vs non carriers (CC), in 
patients under macrolides. The time-dependent clearance of MPA in the 
target population was also confirmed by the model that suggested that CLMPA 
on day 7 was higher than at the remaining monitoring days; however, gradual 
tapering of ciclosporin through concentrations along the post-transplant 
period was not sufficient to describe these changes over time nor other 
covariates whose significance could not be demonstrated as low graft 
function or acidosis or uremia associated to it and consequently low levels of 
albumin.  
 Regarding the metabolites, AcMPAG showed around a ten times faster 
elimination than MPAG, probably due to the highest hydrophilicity of the 
former. Plasmatic clearances of both metabolites were influenced by renal 
function through the estimated CLCR according to the Cockcroft-Gault 
formula, as it should be expected, due to its elimination major pathway by 
urinary excretion [3, 16, 22].  Explicitly, both CLMPAG and CLAcMPAG were 
estimated to increase with renal function. Moreover, CLMPAG decreased in a 
significant statistically way with increasing ciclosporin trough concentrations 
in patients under ciclosporin and similarly to CLMPA, it was higher in C24 
SNP homozygous (TT) or heterozygous (CT) carriers vs non carriers (CC), in 
patients under macrolides. Regarding the influence of C24T SNP in 
CLAcMPAG, it was statistically significant, but only in patients under 
macrolides. By contrast, no statistically significant effect of ciclosporin 
through concentrations on CLAcMPAG could be evidenced.  
 Simulations performed once the model had been evaluated (Fig. 7), 
showed that after multiple fixed doses of MMF (1 g), at one month of the 
post-transplant period, both fMPA and tMPA exposures decreased 
significantly with increasing ciclosporin through concentrations from 100 to 
300 ng/mL. In patients co-treated with macrolides (sirolimus or tacrolimus), 
fMPA and tMPA were significantly lower in homozygous and heterozygous 
variants of the C24T SNP vs wild-type. Among all patients, the highest 
exposure would be observed in wild-type or no variant alleles co-treated with 
sirolimus or tacrolimus while the lowest exposure would be found in patients 
co-treated with standard doses of ciclosporin. Regarding MPAG, exposures 
increased significantly with increasing ciclosporin through concentrations 
(from 100 to 300 ng/mL) and in patients co-treated with macrolides, they 
were significantly lower in homozygous and heterozygous variants of the 
C24T SNP vs wild-type. In the case of ACMPAG, significantly lower 
exposures were observed in homozygous and heterozygous variants of the 
C24T SNP vs wild-type in       patients co-treated with macrolides and also vs the  
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Figure 7. Median values of simulated exposures of fMPA, tMPA and MPAG and 
AcMPAG, after 1 g MMF given orally to patients under ciclosporin with trough 
concentrations of either 100 or 300 ng/mL and to patients under macrolides whether 
non carriers or CT/TT carriers of the C24T SNP of MRP2. The impact of renal 
function given by CLCR estimated according to cockroft-Gault is also shown for 
MPAG and AcMPAG. 
 
remaining patients.  On the other hand, as expected, the major effects on both 
tMPAG and tAcMPAG exposures were due to changes in renal function 
given by CLCR (estimated according to Crokroft-Gault). In effect, 
independently of the co-medication group, exposures significantly decreased 
with increasing CLCR values, the effect was higher for MPAG (around 55% 
from 25 mL/min to 60 mL/min and around 47% from 60 mL/min to 120 
mL/min) than for AcMPAG (around 26% from 25 mL/min to 60 mL/min and 
around 42% from 60 mL/min to 120 mL/min). Then, renal function is the 
most influential covariate in both cases (CLMPAG and CLAcMPAG) followed by 
ciclosporin through concentrations and C24T SNP in the case of MPAG. The 
effect of C24T SNP is more relevant in CLAcMPAG than in CLMAPG. 
Unfortunately, the developed model did not allow the evaluation of the 
impact of changes in renal function on tMPA or fMPA exposures. Regarding 
changes in MPAG exposure with renal function observed in the current work, 
they are comparable to those found by De Winter et al. [28]. In summary we 
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built a population PK model to adequately describe plasma data of tMPA, 
fMPA and its currently known metabolites as a function of co-medication, 
C24T SNP of Mrp2 and renal function. According to it, patients under 
macrolides and non carriers of C24T SNP would require lower doses of 
MMF (around 40% less) than those under standard doses of ciclosporin with 
the same renal function. Since the model development does not allow 
evaluation of the impact of changes in albumin plasma levels and renal 
function on tMPA and fMPA it should be applied to patients with median 
albumin plasma levels of 42 g/L and median CLCR values of 60 mL/min , as 
the median of the population of the current study. 
 
8. Conclusion 
  
 In the present chapter we summarize the relevance of modeling by using 
the population approach in order to describe the pharmacokinetics of 
mycophenolic acid and its metabolites. It allows, not only increasing our 
knowledge to better understand the clinical PK of this drug, but also it may 
prove useful in predicting the PK of MPA and all the characterized 
metabolites after various administration regimens of MMF.  
 Moreover, based on the protein binding model developed, precise 
predictions of fMPA concentrations can be made. This can be useful in at 
least two situations: a) for historical data were only tMPA concentrations are 
available, fMPA concentrations can be predicted and used in developing 
PK/PD relationships, and b) as the tMPA assay is considerably simpler than 
the fMPA assay, measuring only tMPA concentrations may be an alternative 
to measuring fMPA. 
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